Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Making Ranbaxy units...

    Making Ranbaxy units cGMP compliant time consuming: Sun Pharma

    Written by savita thakur thakur Published On 2016-08-22T14:38:47+05:30  |  Updated On 22 Aug 2016 2:38 PM IST
    Making Ranbaxy units cGMP compliant time consuming: Sun Pharma

    New Delhi : Sun Pharma sees remediation process at erstwhile Ranbaxy facilities as a "time consuming" process even as it aims to bring at least one of the plants to conform to current good manufacturing practice regulations (cGMP) in the current fiscal.


    In the company's Annual Report for 2015-16, Sun Pharma Managing Director Dilip Shanghvi also remained bullish on generating targeted synergies of USD 300 million by next fiscal on account of its integration with Ranbaxy Laboratories.


    "We are gradually progressing on the remediation process at the erstwhile Ranbaxy facilities, which were found to be non-compliant in the past. While significant efforts to make these facilities compliant are on, this will be a time-consuming process," Shanghvi said.


    The company expects to complete the remediation steps in at least one of these facilities in this fiscal, he added.


    Currently, all the four manufacturing facilities of Ranbaxy Mohali and Toansa in Punjab, Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh have been banned by the USFDA from export of drugs to the US market.


    In April 2014, Sun Pharma had announced the acquisition of the troubled rival Ranbaxy in an all stock transaction worth USD 4 billion.


    "The implementation of the integration with Ranbaxy is well on its way, and we are on track to generate targeted synergies of USD 300 million by 2017-18," Shangvi said.


    He further said: "The combined organisation will benefit from substantial synergies that lie in our technologies, combined pipeline and R&D expertise, wider product portfolio and rationalisation of manufacturing footprint, driven by our larger talent pool."


    On company's Halol plant, which is under the USFDA scanner for violations of cGMP, Shanghvi said the company faced anticipated supply constraints and delays in product approvals driven by the cGMP compliance remediation efforts.


    "This impacted our US revenues for the year. We expect to eventually resolve this in future. However, this did not deter us from continuing to invest heavily in building the specialty business in the US," he said.


    The drug major continues to invest significant time and resources in ensuring that it remains committed to 24x7 cGMP compliance, Shanghvi said.


    "Over the past year, our cGMP capabilities have been strengthened significantly. Talent with long standing global expertise has enhanced our abilities in this pertinent area. We are also targeting appropriate technology-based solutions to facilitate cGMP compliance, coupled with an increased focus on requisite manpower training," he added.


    On business outlook for the current fiscal, Shanghvi said: "The transformation to a better, stronger and faster company will involve crossing critical milestones over the next few years. As we transition, we have guided for our overall consolidated revenues to grow by 8-10 per cent for this fiscal."

    cGMPcurrent good manufacturing practiceDilip ShanghviRanbaxySun Pharmatime consumingUS Food & Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok